Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHENG Tao ^1,2 , JIN Dacheng ² , CUI Baiqiang ^1,2 , HUANG Daxin ^1,2 ,  GOU Yunjiu ²

1. The First Clinical Department of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, P. R. China;
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China;

Corresponding?author：

GOU Yunjiu, Email: gouyunjiu@163.com

Keywords：

Nedaplatin; cisplatin; gemcitabine; advanced lung squamous cell carcinoma; systematic review/meta-analysis

DOI：

10.7507/1007-4848.202202023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the short-term efficacy and safety of nedaplatin combined with gemcitabine compared with cisplatin combined with gemcitabine in the treatment of advanced lung squamous cell carcinoma. Methods The Cochrane Library, EMbase, PubMed, Web of Science, Wanfang, VIP, CNKI and China General Library of Biomedical Literature were searched. Literatures related to the efficacy and safety of nedaplatin combined with gemcitabine (nedaplatin group) versus cisplatin combined with gemcitabine (cisplatin group) in the treatment of advanced lung squamous cell carcinoma published from the inception to October 2021 were searched. The quality of included studies was assessed by Cochrane bias assessing tool and the meta-analysis was conducted by using RevMan 5.4. Results A total of 10 articles were included covering 914 patients. Meta-analysis showed that the objective remission rate (OR=1.51, 95%CI 1.13-2.01, P=0.005), disease control rate (OR=1.54, 95%CI 1.10-2.15, P=0.01) and 1-year survival rate (OR=2.29, 95%CI 1.25-4.18, P=0.007) of the nedaplatin group were better than those of the cisplatin group. In terms of side effects, the incidence of white blood cell and hemoglobin decline, nausea and vomiting, and diarrhea in the nedaplatin group was lower than that in the cisplatin group (P≤0.05). The differences in the platelet decline and liver and kidney damage between the two groups were not statistically significant (P>0.05). Conclusion For patients with advanced lung squamous cell carcinoma, the short-term efficacy of nedaplatin combined with gemcitabine may be better than cisplatin combined with gemcitabine, and the incidence of adverse reactions is lower.

Citation： CHENG Tao, JIN Dacheng, CUI Baiqiang, HUANG Daxin, GOU Yunjiu. Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(11): 1638-1644. doi: 10.7507/1007-4848.202202023 Copy

1.	International Agency for Research on Cancer. Global cancer observatory: Cancer today. World Health Organization. https://gco. iarc. fr/today (accessed Janyary 19, 2020: ).
2.	Yang QF, Wu D, Wang J, et al. Development and validation of an individualized immune prognostic model in stageⅠ-Ⅲlung squamous cell carcinoma. Sci Rep, 2021, 11(1): 12727.
3.	張家豪, 張亞杰, 李鶴成. 2020年V1版《NCCN非小細胞肺癌臨床實踐指南》更新解讀. 中國胸心血管外科臨床雜志, 2020, 27(6): 614-618.
4.	Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs. chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2021, 7(5): 709-717.
5.	Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol, 2021, 16(9): 1501-1511.
6.	Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med, 2020, 14(2): 125-136.
7.	Kawashima Y, Harada T, Fujita Y, et al. Randomized phaseⅡtrial of carboplatin+nab-paclitaxel versus cisplatin+gemcitabine for chemotherapy-na?ve squamous cell carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol, 2021, 26(3): 515-522.
8.	Choi JH, Choi J, Chung SM, et al. The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma. Tuberc Respir Dis (Seoul), 2019, 82(3): 211-216.
9.	Grossi F, Jaśkiewicz P, Ferreira M, et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: A prospective randomized international phaseⅡstudy (NAVoTrial 03). Ther Adv Med Oncol, 2021, 13: 17588359211022905.
10.	Halvorsen TO, Stokke K, Killingberg KT, et al. Randomized phaseⅢtrial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncol, 2020, 59(9): 1051-1057.
11.	Taniguchi H, Yamaguchi H, Dotsu Y, et al. PhaseⅡstudy of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thorac Cancer, 2019, 10(9): 1764-1769.
12.	黃大新, 韓松辰, 金大成, 等. 奈達鉑對比順鉑聯合氟尿嘧啶治療食管癌療效和安全性的系統評價與Meta分析. 中國胸心血管外科臨床雜志, 2022, 29(11): 1511-1516.
13.	Fu J, Fang S, Wen Y, et al. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. J Buon, 2020, 25(4): 1707-1713.
14.	Lv WZ, Lin Z, Wang SY, et al. PhaseⅡstudy of a bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol, 2019, 12(4): 656-660.
15.	陳勝佳, 朱凱, 林金蘭, 等. 奈達鉑聯合吉西他濱對比順鉑聯合吉西他濱一線治療晚期肺鱗癌隨機對照臨床研究. 中國醫藥科學, 2021, 11(4): 5-8, 46.
16.	曹子肖, 周麗亞, 劉佳慧, 等. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的近期療效觀察. 蚌埠醫學院學報, 2021, 46(4): 475-479.
17.	趙淑芬, 肖文靜, 劉寧, 等. 吉西他濱聯合奈達鉑治療晚期肺鱗癌患者的療效分析. 中國實用醫藥, 2016, 11(11): 124-125.
18.	舒誠榮, 曹愛玲. 吉西他濱聯合奈達鉑治療晚期肺鱗癌34例療效觀察. 海南醫學, 2014, (13): 1970-1972.
19.	陳澤勉. 晚期肺鱗癌采取奈達鉑與順鉑結合吉西他濱化療的效果對比分析. 北方藥學, 2019, 16(7): 15-16.
20.	張容軒. 西他濱分別聯合順鉑和奈達鉑治療晚期肺鱗癌的療效及安全性分析. 臨床合理用藥, 2017, 10(11): 46-48.
21.	張晶, 陳群, 柯明耀, 等. 奈達鉑聯合吉西他濱與順鉑聯合吉西他濱一線治療晚期肺鱗癌隨機對照臨床研究. 國際腫瘤學雜志, 2017, 44(1): 15-18.
22.	羅小寧, 張羽, 郭蒸. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的臨床療效觀察. 中國現代醫生, 2020, 58(27): 118-120, 124.
23.	張蕾, 張敬偉, 王羽喆. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的臨床觀察. 當代醫學, 2014, (26): 141-142.
24.	晏軍, 曹純. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的療效觀察. 四川醫學, 2017, 38(2): 199-201.
25.	Gao M, Zhou Q. Progress in treatment of advanced squamous cell lung cancer. Zhongguo Fei Ai Za Zhi, 2020, 23(10): 866-874.
26.	Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019, 88: 102925.
27.	Qi L, Luo Q, Zhang Y, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol, 2019, 32(8): 1469-1486.
28.	Paroha S, Verma J, Dubey RD, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm, 2021, 592: 120043.
29.	Ikeda S, Yoshioka H, Kaneda T, et al. A phaseⅡstudy of cisplatin plus gemcitabine followed by maintenance gemcitabine for advanced squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group 1302. Oncology, 2019, 97(6): 327-333.
30.	Yue J, Hu NL, Wang X, et al. Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer. Zhonghua Zhong Liu Za Zhi, 2021, 43(8): 883-888.
31.	Lu S, Chen Z, Hu C, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung—A multicenter, open-label, randomized, phase Ⅲ trial. J Thorac Oncol, 2018, 13(11): 1743-1749.
32.	徐赟, 衛立辛. 吉西他濱聯合奈達鉑治療的非小細胞肺癌患者血清CDA水平變化及意義. 中國醫院藥學雜志, 2019, 39(24): 2537-2541.
33.	陳永倖, 符詒慧, 蒙沖. 吉西他濱聯合奈達鉑一線治療晚期非小細胞肺癌的臨床療效及安全性評價. 臨床內科雜志, 2019, 36(7): 476-478.
34.	房輝, 許淑云, 湯瑩, 等. 吉西他濱聯合奈達鉑治療晚期肺癌患者的效果分析. 腫瘤藥學, 2019, 9(2): 296-299.
35.	Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 2014, 15(2): 731-736.
36.	Shan J, Xiong Y, Wang D, et al. Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Mol Clin Oncol, 2015, 3(3): 543-549.
37.	Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol, 2015, 16(16): 1630-1638.
38.	胡永梅, 張浩玲, 何霞, 等. 奈達鉑或順鉑聯合紫杉醇治療晚期非小細胞肺癌和食管癌的系統評價. 中國藥房, 2016, 27(24): 3397-3400.

1. International Agency for Research on Cancer. Global cancer observatory: Cancer today. World Health Organization. https://gco. iarc. fr/today (accessed Janyary 19, 2020: ).
2. Yang QF, Wu D, Wang J, et al. Development and validation of an individualized immune prognostic model in stageⅠ-Ⅲlung squamous cell carcinoma. Sci Rep, 2021, 11(1): 12727.
3. 張家豪, 張亞杰, 李鶴成. 2020年V1版《NCCN非小細胞肺癌臨床實踐指南》更新解讀. 中國胸心血管外科臨床雜志, 2020, 27(6): 614-618.
4. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs. chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2021, 7(5): 709-717.
5. Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol, 2021, 16(9): 1501-1511.
6. Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med, 2020, 14(2): 125-136.
7. Kawashima Y, Harada T, Fujita Y, et al. Randomized phaseⅡtrial of carboplatin+nab-paclitaxel versus cisplatin+gemcitabine for chemotherapy-na?ve squamous cell carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol, 2021, 26(3): 515-522.
8. Choi JH, Choi J, Chung SM, et al. The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma. Tuberc Respir Dis (Seoul), 2019, 82(3): 211-216.
9. Grossi F, Jaśkiewicz P, Ferreira M, et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: A prospective randomized international phaseⅡstudy (NAVoTrial 03). Ther Adv Med Oncol, 2021, 13: 17588359211022905.
10. Halvorsen TO, Stokke K, Killingberg KT, et al. Randomized phaseⅢtrial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncol, 2020, 59(9): 1051-1057.
11. Taniguchi H, Yamaguchi H, Dotsu Y, et al. PhaseⅡstudy of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thorac Cancer, 2019, 10(9): 1764-1769.
12. 黃大新, 韓松辰, 金大成, 等. 奈達鉑對比順鉑聯合氟尿嘧啶治療食管癌療效和安全性的系統評價與Meta分析. 中國胸心血管外科臨床雜志, 2022, 29(11): 1511-1516.
13. Fu J, Fang S, Wen Y, et al. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. J Buon, 2020, 25(4): 1707-1713.
14. Lv WZ, Lin Z, Wang SY, et al. PhaseⅡstudy of a bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol, 2019, 12(4): 656-660.
15. 陳勝佳, 朱凱, 林金蘭, 等. 奈達鉑聯合吉西他濱對比順鉑聯合吉西他濱一線治療晚期肺鱗癌隨機對照臨床研究. 中國醫藥科學, 2021, 11(4): 5-8, 46.
16. 曹子肖, 周麗亞, 劉佳慧, 等. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的近期療效觀察. 蚌埠醫學院學報, 2021, 46(4): 475-479.
17. 趙淑芬, 肖文靜, 劉寧, 等. 吉西他濱聯合奈達鉑治療晚期肺鱗癌患者的療效分析. 中國實用醫藥, 2016, 11(11): 124-125.
18. 舒誠榮, 曹愛玲. 吉西他濱聯合奈達鉑治療晚期肺鱗癌34例療效觀察. 海南醫學, 2014, (13): 1970-1972.
19. 陳澤勉. 晚期肺鱗癌采取奈達鉑與順鉑結合吉西他濱化療的效果對比分析. 北方藥學, 2019, 16(7): 15-16.
20. 張容軒. 西他濱分別聯合順鉑和奈達鉑治療晚期肺鱗癌的療效及安全性分析. 臨床合理用藥, 2017, 10(11): 46-48.
21. 張晶, 陳群, 柯明耀, 等. 奈達鉑聯合吉西他濱與順鉑聯合吉西他濱一線治療晚期肺鱗癌隨機對照臨床研究. 國際腫瘤學雜志, 2017, 44(1): 15-18.
22. 羅小寧, 張羽, 郭蒸. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的臨床療效觀察. 中國現代醫生, 2020, 58(27): 118-120, 124.
23. 張蕾, 張敬偉, 王羽喆. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的臨床觀察. 當代醫學, 2014, (26): 141-142.
24. 晏軍, 曹純. 吉西他濱聯合奈達鉑治療晚期肺鱗癌的療效觀察. 四川醫學, 2017, 38(2): 199-201.
25. Gao M, Zhou Q. Progress in treatment of advanced squamous cell lung cancer. Zhongguo Fei Ai Za Zhi, 2020, 23(10): 866-874.
26. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019, 88: 102925.
27. Qi L, Luo Q, Zhang Y, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol, 2019, 32(8): 1469-1486.
28. Paroha S, Verma J, Dubey RD, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm, 2021, 592: 120043.
29. Ikeda S, Yoshioka H, Kaneda T, et al. A phaseⅡstudy of cisplatin plus gemcitabine followed by maintenance gemcitabine for advanced squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group 1302. Oncology, 2019, 97(6): 327-333.
30. Yue J, Hu NL, Wang X, et al. Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer. Zhonghua Zhong Liu Za Zhi, 2021, 43(8): 883-888.
31. Lu S, Chen Z, Hu C, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung—A multicenter, open-label, randomized, phase Ⅲ trial. J Thorac Oncol, 2018, 13(11): 1743-1749.
32. 徐赟, 衛立辛. 吉西他濱聯合奈達鉑治療的非小細胞肺癌患者血清CDA水平變化及意義. 中國醫院藥學雜志, 2019, 39(24): 2537-2541.
33. 陳永倖, 符詒慧, 蒙沖. 吉西他濱聯合奈達鉑一線治療晚期非小細胞肺癌的臨床療效及安全性評價. 臨床內科雜志, 2019, 36(7): 476-478.
34. 房輝, 許淑云, 湯瑩, 等. 吉西他濱聯合奈達鉑治療晚期肺癌患者的效果分析. 腫瘤藥學, 2019, 9(2): 296-299.
35. Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 2014, 15(2): 731-736.
36. Shan J, Xiong Y, Wang D, et al. Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Mol Clin Oncol, 2015, 3(3): 543-549.
37. Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol, 2015, 16(16): 1630-1638.
38. 胡永梅, 張浩玲, 何霞, 等. 奈達鉑或順鉑聯合紫杉醇治療晚期非小細胞肺癌和食管癌的系統評價. 中國藥房, 2016, 27(24): 3397-3400.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content